At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 101 enrolled
Drug / intervention
silk suture +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery
In Brief
A Phase 4 clinical trial evaluating silk suture and VICRYL* Plus suture for Breast Cancer. Completed, enrolled 101 participants across 6 sites.
Detailed Summary
This is a 90-day study to evaluate cosmetic outcome and Surgical Site Infection in approximately 100 patients from 6 centers in China undergoing scheduled modified radical mastectomy for breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsJohnson & Johnson Medical, China
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionMar 2009
Study CompletionMay 2009
TodayJul 2026
First PostedOct 8, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.7 years ago
Interventions
silk suturedevice
skin closure
VICRYL* Plus suturedevice
skin closure